VolitionRx’s (VNRX) “Buy” Rating Reaffirmed at D. Boral Capital

D. Boral Capital restated their buy rating on shares of VolitionRx (NYSE:VNRX) in a research note issued to investors on Wednesday morning,Benzinga reports. The firm currently has a $5.00 price target on the stock.

Several other brokerages have also weighed in on VNRX. StockNews.com initiated coverage on VolitionRx in a research report on Thursday, January 23rd. They issued a “sell” rating on the stock. Benchmark restated a “hold” rating on shares of VolitionRx in a report on Friday, November 22nd.

VolitionRx Stock Performance

VolitionRx stock opened at $0.61 on Wednesday. VolitionRx has a 12 month low of $0.43 and a 12 month high of $1.23. The company’s fifty day simple moving average is $0.64 and its 200-day simple moving average is $0.66.

Insiders Place Their Bets

In other news, Director Guy Archibald Innes bought 174,764 shares of the business’s stock in a transaction on Monday, December 9th. The stock was purchased at an average price of $0.57 per share, with a total value of $99,615.48. Following the transaction, the director now directly owns 617,085 shares in the company, valued at approximately $351,738.45. The trade was a 39.51 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Cameron John Reynolds purchased 139,811 shares of the firm’s stock in a transaction on Monday, December 9th. The shares were purchased at an average price of $0.57 per share, with a total value of $79,692.27. Following the completion of the acquisition, the chief executive officer now directly owns 2,117,404 shares of the company’s stock, valued at approximately $1,206,920.28. This trade represents a 7.07 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired 358,266 shares of company stock valued at $204,212 over the last three months. 12.80% of the stock is currently owned by insiders.

Hedge Funds Weigh In On VolitionRx

An institutional investor recently raised its position in VolitionRx stock. Ground Swell Capital LLC boosted its holdings in VolitionRx Limited (NYSE:VNRX) by 78.8% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 45,959 shares of the company’s stock after buying an additional 20,249 shares during the period. Ground Swell Capital LLC’s holdings in VolitionRx were worth $28,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 8.09% of the company’s stock.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.